Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. pmc.ncbi.nlm.nih.gov › articles › PMC6261117Treatment of Atopic Dermatitis with Biologic Drugs - PMC

   pmc.ncbi.nlm.nih.gov › articles › PMC6261117

   Atopic dermatitis (AD) is the most common inflammatory skin disease of childhood, affecting about 20% of children [1]. AD usually resolves before adolescence. However, it sometimes persists in adulthood (persistent AD), and in some cases the disease starts in adulthood (adult-onset AD) [2]. It is reported that the prevalence of childhood AD is ...

2. ncbi.nlm.nih.gov › pmc › articlesBiologics for pediatric atopic dermatitis: A protocol of a...

   ncbi.nlm.nih.gov › pmc › articles

   3 Φεβ 2023 · Background. Atopic dermatitis is a chronic pruritic inflammatory skin disease commonly occurring in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with biologics, as they have displayed immense promising results in several recent clinical trials on atopic dermatitis (AD). Methods.

3. pmc.ncbi.nlm.nih.gov › articles › PMC8648434The New Era of Biologics in Atopic Dermatitis: A Review

   pmc.ncbi.nlm.nih.gov › articles › PMC8648434

   Abstract. Atopic dermatitis (AD) is a prevalent inflammatory skin disorder affecting all age and ethnic groups. The age-dependent varying appearance and extent of pruritic lesions are accompanied by distinct individual suffering, highlighting the importance of effective treatment options.

4. www.jacionline.org › article › S0091-6749(23)00083-0Biologics in the management of childhood atopic dermatitis

   www.jacionline.org › article › S0091-6749(23)00083-0

   16 Αυγ 2022 · Dupilumab, the only US Food and Drug Administration (FDA)-approved biologic for children with moderate-to-severe AD as young as 6 months, blocks IL-4Rα, thus inhibiting signaling activated by IL-4 and IL-13 through the IL-4Rα/IL-13R1α heterodimer.

5. www.thelancet.com › journals › lancetBiological therapy for young children with atopic dermatitis

   www.thelancet.com › journals › lancet

   The trial results are encouraging and show that moderate-to-severe atopic dermatitis can be reduced and controlled in even very young children. However, because most children included in the study were aged 2 years or older (151 [93%]), efficacy and safety data on dupilumab treatment in infants are still scarce.

6. pmc.ncbi.nlm.nih.gov › articles › PMC7018348Childhood atopic dermatitis: current developments, treatment...

   pmc.ncbi.nlm.nih.gov › articles › PMC7018348

   Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder of childhood. Underlying factors that contribute to AD are impaired epithelial barrier, alterations in the lipid composition of the skin, immunological imbalance including ...

7. www.ncbi.nlm.nih.gov › pmc › articlesCurrent Perspectives on the Management of Infantile Atopic...

   www.ncbi.nlm.nih.gov › pmc › articles

   5 Νοε 2020 · Currently, the only approved systemic treatment for childhood AD is dupilumab in patients aged 6 years and older. However, clinical trials investigating the efficacy and safety of novel topical and systemic therapies for infantile and childhood AD are ongoing.